Elvina Almuradova/X
Sep 21, 2024, 19:35
Elvina Almuradova: The NCT03886441 trial
Elvina Almuradova, Associate Professor, Medicana Health Group, shared a post on X:
“The NCT03886441 trial, where the addition of beclomethasone significantly reduced the rate of radiotherapy-induced pneumonia, delivered impressive results.
Interventions like this are simple, accessible, cost-effective, and can be easily implemented in clinics worldwide, offering a real improvement in patients’ quality of life.
Further phase III trials are essential.
– Reduced radiation pneumonitis: 35.3% vs. 52.8% (P=0.03)
– Severe cases dropped: 12% vs. 28.2% (P=0.01)
– No difference in overall survival
– Increased hyperglycemia in steroid group (P=0.025).”
Source: Elvina Almuradova/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54